Fiala

Peptide library › Cancer & imaging

Lutetium Lu-177 dotatate

Also known as Lutathera, 177Lu-DOTATATE, PRRT

FDA-approved drugCancer & imaging

Targeted radiation therapy that delivers radiation straight to neuroendocrine tumours.

What people use it for

What Lutetium Lu-177 dotatate does in the body

A somatostatin-like peptide carrying radioactive lutetium-177. It homes in on tumour cells that carry somatostatin receptors and irradiates them from close range.

Strength of evidence

Strong: the NETTER-1 trial greatly delayed tumour growth.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2018 for adults, later extended to adolescents. Given in specialist nuclear medicine centres.

How it's taken

Route: Four infusions into a vein, about 8 weeks apart

How long it lasts (half-life): Lutetium-177 loses half its radioactivity every 6.7 days

Storage

Stored and prepared by the pharmacy or clinic, following the product label.

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Lutetium Lu-177 dotatate privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Lutetium Lu-177 dotatate in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Cancer & imaging